



Townsend, E. M., Sherry, L., Rajendran, R., Hansom, D., Butcher, J., Mackay, W. G., Williams, C., and Ramage, G. (2016) Development and characterisation of a novel three-dimensional inter-kingdom wound biofilm model. *Biofouling*, 32(10), pp. 1259-1270.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/131921/>

Deposited on: 25 November 2016

Enlighten – Research publications by members of the University of Glasgow
<http://eprints.gla.ac.uk>

Title: Development and characterisation of a novel three-dimensional interkingdom wound biofilm model

Eleanor M Townsend^{1,2}, Leighann Sherry^{1,2}, Ranjith Rajendran¹ Donald Hansom¹, John Butcher², William G Mackay², Craig Williams² and Gordon Ramage^{*1}

¹Oral Sciences Research Group, Glasgow Dental School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK, ²Institute of Healthcare Policy and Practice, University of West of Scotland, Paisley, UK

*Corresponding Author: Gordon Ramage, Oral Sciences Research Group, Glasgow Dental School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, 378 Sauchiehall Street, Glasgow, G2 3JZ, UK. Phone: +44(0)141 211 9752. e-mail: gordon.ramage@glasgow.ac.uk

1 **Abstract**

2 Chronic diabetic foot ulcers are frequently colonised and infected by
3 polymicrobial biofilms that ultimately prevents healing. In this study, we aimed
4 to create a novel *in vitro* inter-kingdom wound biofilm model on complex
5 hydrogel-based cellulose substrates to test commonly used topical wound
6 treatments. Inter-kingdom triadic biofilms composed of *Candida albicans*,
7 *Pseudomonas aeruginosa*, and *Staphylococcus aureus* were shown to be
8 quantitatively greater in this model compared to a simple substrate when
9 assessed by conventional culture, metabolic dye and live dead qPCR. These
10 biofilms were both structurally complex and compositionally dynamic in
11 response to topical therapy, so when treated with either chlorhexidine or
12 povidone iodine principal component analysis revealed that the 3-D cellulose
13 model was minimally impacted compared to the simple substrate model. This
14 study highlights the importance of biofilm substrate and inclusion of relevant
15 polymicrobial and inter-kingdom components, as these impact penetration and
16 efficacy of topical antiseptics.

17

1 **Background**

2 Chronic wounds are associated with unacceptably high morbidity and mortality
3 rates, in addition to being a significant economic burden to the National Health
4 Service (NHS) in the UK. It is estimated that the NHS spends in the region of
5 £900 million per year on diabetic foot ulcer treatments and resultant
6 amputations (Hex et al. 2012). Infection risk is one of the overriding factors
7 driving these costs and complications, and the capacity of endogenous and
8 exogenous microorganisms to form complex biofilms within these
9 compromised skin environments hinders chemotherapeutic management (Alavi
10 et al. 2014).

11
12 Pathogenic biofilms are frequently associated with chronic wounds (James et
13 al. 2008, Neut et al. 2011). These structures complicate treatment strategies
14 due to enhanced adaptive resistance profiles, primarily driven by the physical
15 composition, including the production of extracellular matrix (ECM) that
16 prevents diffusion of antimicrobials into the biofilm (Davies 2003, Pozo and
17 Patel 2007, Ramage et al. 2012a). ECM-associated degradative enzymes,
18 hypermutability, and persister cells, are just a few examples of how these
19 complex communities survive and adapt to antimicrobial challenge (Davies
20 2003, Høiby et al. 2010, Pozo and Patel 2007, Ramage, et al. 2012a).
21 Complicating chemotherapeutic intervention even further is the polymicrobial
22 nature of the biofilms found in diabetic foot ulcers (Smith et al. 2016). Moreover,
23 increasing evidence that yeasts and moulds play important contributory roles in
24 exacerbating infections suggests inter-kingdom biofilms deserve consideration
25 (Peters et al. 2012).

26
27 *S. aureus* and *P. aeruginosa* are the two most frequently isolated bacterial
28 species from such chronic and difficult-to-treat biofilm infections (Citron et al.
29 2007, Hartemann - Heurtier et al. 2004, MacDonald et al. 2002). They are
30 often co-isolated and are associated geographically within the wound site
31 (Fazli et al. 2009). In contrast to bacteria, despite reports their importance, the
32 role of pathogenic fungi in wound biofilms, are relatively under-investigated and
33 underappreciated clinical entities (Appelgren et al. 2002, Dowd et al. 2011,

1 MacDonald, et al. 2002, Santucci et al. 2003, Sun 2010, Weinstein and
2 Mayhall 2003). *Candida* species are the primary fungal pathogen isolated from
3 these infections, although this organism rarely colonises healthy intact skin
4 (Grice and Segre 2011). Several models have been described in recent years
5 that have examined these paradigm nosocomial pathogens in triadic systems
6 (Hoekstra et al. 2016, Kart et al. 2014). Though a caveat to the utility and
7 translation of these models is the basic 2-dimensional nature of the substrates
8 used, which are not at all representative of a wound environment (Hill et al.
9 2010, Hoekstra, et al. 2016, Kart, et al. 2014). The development of cellulose
10 matrix based models supported by hydrogels that better mimic the consistency
11 of the wound surface enables biofilms to form in a 3-dimensional matrix. Using
12 either poloxamer, collagen, or agarose hydrogel, a complex hydrated structure
13 is formed which induces the development of the biofilm phenotype (Clutterbuck
14 et al. 2007, Harrison et al. 2015, Percival et al. 2007, Strathmann et al. 2000).
15 The main applicability and translation usefulness of these model systems lies
16 in their utility in the development and testing of antimicrobial anti-biofilm
17 molecules. To date, these models have tended to focus on mono-species
18 biofilms.

19
20 Systemic antibiotics are commonly used to treat chronic wounds, yet there is
21 controversy over their usage and rising concerns over the development of
22 antimicrobial resistant organisms (Atiyeh et al. 2009, O'meara et al. 2001).
23 Topical wound washes and ointments are often recommended as an
24 alternative to, or in combination with, systemic treatment (Atiyeh, et al. 2009,
25 Snell et al. 2013). Chlorhexidine (CHX) and povidone iodine (PVP-I) are two of
26 the most commonly used clinically due to their high levels of biocidal activity
27 (Atiyeh, et al. 2009, O'meara, et al. 2001).

28
29 The aims of the present study were therefore to develop a polymicrobial inter-
30 kingdom *in vitro* biofilm model on complex substrates that can be used to test
31 clinically relevant antimicrobial therapeutics. Here we show for the first time the
32 use of a novel biofilm substrate that can be adapted to represent a wide variety
33 of wound infection biofilms, and its application for chronic wound biofilm
34 research.

1 **Methods**

2 ***Culture conditions and standardisation***

3 A selection of characterised laboratory strains were used in this study,
4 including the bacteria *P. aeruginosa* PA14 (Rahme et al. 1995), *S. aureus*
5 Newman's strain (Duthie and Lorenz 1952) and the yeast *Candida albicans*
6 SC5314 (Fonzi and Irwin 1993). Both bacteria were grown and maintained at
7 37°C on Luria agar (Sigma-Aldrich, Dorset, UK), while *C. albicans* was grown
8 and maintained at 30°C on Sabouraud dextrose agar (SAB [Sigma-Aldrich,
9 Dorset, UK]). All isolates were stored indefinitely in Microbank[®] vials (Pro-Lab
10 Diagnostics, Cheshire, UK) at -80°C.

11 Overnight broths of *P. aeruginosa* and *S. aureus* were prepared in 10 mL Luria
12 broth ([LB] Sigma-Aldrich, Dorset, UK) at 37°C and *C. albicans* was
13 propagated in 10 mL yeast peptone dextrose broth (YPD [Sigma-Aldrich,
14 Dorset, UK]) at 30°C at 150 rpm. Overnight cultures were washed twice by
15 centrifugation (1600 x g) and resuspended in 10 mL phosphate buffered saline
16 (PBS). All cultures were standardised and adjusted to 1×10^8 cells/mL, using
17 optical density at 590 nm for bacterial strains and a haemocytometer for *C.*
18 *albicans*.

19

20 ***Hydrogel preparation***

21 Hydrogels were composed of 10% 3-sulfopropyl acrylate potassium salt, 0.95%
22 v/v poly(ethylene glycol) deacrylate (PEG), 0.01% v/v 1- hydroxycyclohexyl
23 phenyl ketone, with the addition of 50% heat-inactivated horse serum ([HS]
24 Thermo Fisher Scientific, Loughborough, UK) in sterile water to the final
25 volume. To a 12-well flat-bottomed microtiter plates (Corning Incorporated, NY,
26 USA), 2 mL of hydrogel was added to each well before being polymerised
27 under a 366 nm ultraviolet (UV) Lamp (Camag, Hungerford, UK) for 30 min
28 within a class II laminar flow hood. These polymerised hydrogels were then
29 stored at 4°C until required, for up to one week.

Biofilm development and antimicrobial therapy

All organisms were standardised to a final working concentration of 1×10^6 cells/mL in 50% v/v HS (Life Technologies, Paisley, UK) for biofilm development. For viability and biomass assays (described below), 200 μ L of single species and triadic species suspensions were added to 96-well flat-bottomed microtiter plates (Corning Incorporated, NY, USA). For quantitative polymerase chain reaction (qPCR) and viable cell counting, 500 μ L of cultures were added to Thermanox™ coverslips (13 mm diameter, Fisher Scientific) contained within 24 well plates (Corning, NY, USA). Biofilms were incubated at 37°C for 24 h to develop. All procedures were carried out in a class II laminar flow hood. For biofilm development on hydrogels, organisms were standardised to a 1×10^6 cells/mL in PBS and added to sections of cellulose matrix (1.25 cm²) (IPS Converters, Oldham, UK). Following initial incubation at 37°C with agitation for 2 h, the matrix was then placed on top of the hydrogel surface and incubated at 37°C for 24 h. Negative controls containing no inoculum were also included. All testing was carried out in triplicate, on three separate occasions. Following biofilm development, cells were washed twice with PBS to remove any non-adherent cells before treatment with 10% w/v PVP-I (Sigma) or 0.05% v/v CHX (Sigma) for a further 24 h at 37°C. Untreated controls were also included.

Assessment of treatment using conventional quantitative culture

To assess the viability of the organisms contained within the biofilm, viable cell counting was performed. Following treatment, biofilms were sonicated in 1 mL PBS, from Thermanox™ coverslips or hydrogel cellulose matrix at 35 kHz for 10 min to remove the biomass, as described previously (Ramage et al. 2012b), prior to the Miles and Misra technique (Miles et al. 1938). Decimal serial dilutions were plated on LB and SAB agar, which were incubated at 37°C and 30°C, respectively for 72 h for Thermanox™ coverslips, and 48 h for hydrogel. The number of colonies were counted and represented as total bacteria and total yeast colony forming units (CFU) per mL.

Assessment of treatments using quantitative viability assays

Following treatment, biofilms were washed twice with PBS before biofilm viability and biomass were quantified. Viability was assessed by the AlamarBlue[®] assay (Invitrogen, Paisley, UK), as per manufacturer's instructions (Kirchner et al. 2012). Absorbance was measured spectrophotometrically at 570 nm and the reference wavelength at 600 nm (FluoStar Omega, BMG Labtech). All assays were performed in triplicate, on three separate occasions.

Assessment of treatment using live/dead quantitative PCR

Viability based qPCR, a technique shown to differentiate between viable and dead cells (Alvarez et al. 2013, Sanchez et al. 2013, Sanchez et al. 2014, Sherry et al. 2016), was used to assess the composition and viability of the biofilms at a molecular level. Samples were prepared as previously described by our group using propidium monoazide (PMA), a DNA intercalating dye, which prevents DNA from cells with compromised membranes from being detected by PCR (Sherry, et al. 2016). Briefly, biofilms were sonicated from Thermanox[™] coverslips or cellulose matrix, 50 μ M of PMA was added to each sample before incubation in the dark for 10 min to allow dye uptake. To permit binding of the PMA, samples were exposed to a 650 W halogen light for 5 min. DNA was then extracted using the QIAamp DNA mini kit, as per manufacturer's instructions (Qiagen, Crawley, UK). Controls containing no PMA were also included for each sample to determine total biomass.

Following DNA extraction, qPCR was used to enumerate both the live and total cells of each species remaining in the biofilm following each treatment. In brief, 1 μ L of extracted DNA was added to a mastermix which contained 10 μ L Fast SYBR[®] Green Master Mix (Life Technologies, Paisley, UK), 7 μ L water and 1 μ L of 10 μ M forward and reverse primers for each bacterial or fungal species. Primer sequences are shown in Table 1. The thermal profile of 95°C for 20 s followed by 40 cycles of 3 s at 95°C, and 30 s at 60°C was used in this study. Three independent replicates for each treatment were analysed in duplicate

1 using Step One Real-Time PCR system and software (Life Technologies,
2 Paisley, UK). Samples were quantified to calculate the colony forming
3 equivalent (CFE) based upon a standard curve per reaction performed.

5 ***Scanning electron microscopy***

6 Biofilms were grown on Thermanox™ coverslips or hydrogel cellulose matrix
7 and treated, as previously described. Biofilms were washed twice with PBS,
8 before being fixed in 2% para-formaldehyde, 2% glutaraldehyde, 0.15M
9 sodium cacodylate, and 0.15% w/v alcian blue, at pH 7.4, and prepared for
10 SEM as previously described (Erlandsen et al. 2004). The specimens were
11 sputter-coated with gold and viewed under a JEOL JSM-6400 scanning
12 electron microscope.

14 ***Statistical analysis***

15 Graph production, data distribution and statistical analysis were performed
16 using GraphPad Prism (version 6; La Jolla, CA, USA). Unpaired t-tests were
17 used to establish significant differences between treatments and substrate
18 types for viability assay scores and CFEs. Percentage viability scores were log
19 transformed before statistical analysis took place. For conventional quantitative
20 culture, Mann-Whitney test was used. Statistical significance was achieved if
21 $P < 0.05$. Next, viable composition datasets were reduced by \log_2 transformation
22 so as to carry out principal component analysis (PCA) using PAST software
23 (Hammer O 2001). A scree plot was used to determine how many components
24 emerged. To determine if statistically distinct clusters formed on the PCA plots,
25 new variables were created for each principle component by using the factor
26 loadings as regression coefficients, producing a score for each sample. These
27 scores were then used as outcome variables to compare between groups
28 using an unpaired t-test.

1 Results

2 ***Standard 2-D biofilm models show antibacterial agent efficacy in mono-*** 3 ***species, while triadic biofilms support some resistance***

4 Firstly, we wanted to establish a baseline using a typical substrate used for *in*
5 *vitro* biofilm studies, i.e. a 2-D polystyrene model. Here we tested two key
6 topical agents using conventional culture, and based upon this methodology
7 PVP-I was shown to be the most effective treatment, completely eradicating
8 the bacterial and yeast biofilm burden of all mono-cultures ($P < 0.0001$) (Figure
9 1A). In addition, CHX was equally active against *P. aeruginosa* mono-culture
10 biofilms and bacteria in the triadic species biofilms, significantly reducing total
11 bacterial counts by $>6 \log_{10}$ (Figures 1A and 1B). *S. aureus* and *C. albicans*
12 mono-species biofilms were also reduced by CHX treatment (Figure 1A), but
13 only by $>2 \log_{10}$ ($P < 0.05$, $P < 0.001$, respectively). However, in the 2-D triadic
14 model yeast counts were completely unaffected (Figure 1B).

15 Using soluble metabolic dyes (Figure 1C), in the 2-D model *C. albicans* and *P.*
16 *aeruginosa* mono-culture viability was significantly reduced by both PVP-I and
17 CHX ($P < 0.0001$). CHX was able to significantly inhibit *S. aureus* biofilms
18 ($P < 0.05$), but PVP-I showed no significant reduction. In contrast, in the triadic
19 culture both CHX and PVP-I caused significant decreases in viability
20 ($P < 0.0001$).

21

22 ***Molecular analysis reveals reservoirs of viable cells remain after*** 23 ***treatment of 2-D mono-species and triadic biofilms***

24 The techniques described above are subjective in terms of species-specific
25 quantification, so given these limitations we decided to employ a molecular
26 approach, enabling determination of the precise viable composition of biofilms
27 following active exposure. Despite culture and metabolic evaluation showing a
28 significant reduction in the viability of all biofilms, viable quantitative analysis by
29 qPCR revealed a significant number of cells are retained within each biofilm

(Figure 2 and 3). Molecular analysis consistently showed higher reductions with PVP-I compared to CHX treatment in both substrates tested.

C. albicans mono-species total cell count was significantly reduced with both PVP-I ($P<0.0001$) and CHX ($P<0.001$) treatment (Figure 2A). The number of live cells remaining within those treated biofilms was 13% ($P<0.0001$) and 23% ($P<0.01$), respectively. *S. aureus* mono-species total cell count was also significantly reduced (88.5%) with PVP-I ($P<0.0001$), with only 2% live cells remaining ($P<0.0001$) (Figure 2B). CHX treatment, however, showed no difference to the control for both total and live cells ($P>0.05$). *P. aeruginosa* mono-species biofilms were also affected by the two treatments (Figure 2C). *P. aeruginosa* mono-species total cells were significantly reduced by PVP-I (77%, $P<0.01$), and live cells reduced by 98% ($P<0.05$). CHX treatment appeared to cause a significant increase in total cell count ($P<0.01$), though a slight decrease in live cells ($P>0.05$).

The triadic species biofilms were again more effectively treated by PVP-I compared to CHX (Figure 3). The total cell count on the 2-D model was significantly reduced by PVP-I (92%, $P<0.0001$; Figure 3B). Live cells were similarly reduced compared to untreated biofilms (98%, $P<0.001$; Figure 3A). CHX caused a significant increase in total cells, rising by ~2.5 times ($P<0.0001$), whereas live cells marginally decreased (20%, $P>0.05$; Figure 3C).

SEM analysis was used to analyse the biofilm architecture \pm treatment (Figure 3). In the 2-D model *C. albicans* was mainly hyphae, acting as a scaffold to which the bacteria tended to co-aggregate upon (see insert magnification). The cell density within the biofilm was reduced by both treatments, although more so with PVP-I.

3-D substrates support culturably greater quantities of mono-species and triadic biofilm cells with enhanced resistance to CHX and PVP-I

Using conventional culture, the 3-D cellulose matrix model, with PVP-I treatment (Figure 4A) significantly reduced *C. albicans*, *S. aureus*, and *P.*

1 *aeruginosa* monocultures ($P<0.0001$), whereas CHX was ineffective for both *C.*
2 *albicans* and *P. aeruginosa* ($P>0.05$). *S. aureus*, however, was significantly
3 decreased by CHX ($P<0.0001$; Figure 4A). In the triadic hydrogel model,
4 yeasts and bacteria were significantly reduced by PVP-I ($P<0.0001$), but not
5 CHX ($P>0.05$; Figure 4B). The metabolic assays confirmed these results
6 (Figure 4C), with both *C. albicans* and *S. aureus* monocultures were
7 significantly reduced by the two treatments ($P<0.0001$). *P. aeruginosa* and
8 triadic cellulose matrix biofilms, although both significantly reduced with PVP-I
9 treatment ($P<0.0001$), were seemingly unaffected by CHX treatment, ($P>0.05$).

10

11 ***3-D substrates support greater total and viable quantities of mono-and***
12 ***triadic species biofilm cells with enhanced resistance to CHX and PVP-I***

13 Overall, the treatments on 3-D cellulose matrix mono-species biofilms showed
14 similar efficacy patterns to the 2-D model, although, 3-D cellulose matrix
15 models generally had higher numbers of total and viable cells ($P<0.05$) (Figure
16 5). *C. albicans* mono-culture total cell count was reduced by 72% by PVP-I
17 ($P<0.01$), whereas CHX was less effective with a 28% reduction ($P>0.05$)
18 (Figure 5A). The live cell count within these biofilms was significantly reduced
19 by 98% and 61% after PVP-I ($P<0.001$) and CHX treatment ($P<0.05$),
20 respectively. Both total and live cell counts for *S. aureus* were reduced by
21 approximately 88% by PVP-I ($P<0.001$) and 98% ($P<0.05$), respectively
22 (Figure 5B). Treatment with CHX was ineffective for total and live cells
23 ($P>0.05$). CHX reduced *P. aeruginosa* total cells by only 15%, and viable cells
24 were unaffected ($P>0.05$) (Figure 5C). PVP-I, however, was significantly
25 effective reducing total cell count by 84% ($P<0.001$) and live cell count by 95%
26 ($P<0.001$).

27 The triadic 3-D model showed a total cell count reduction by 94% with PVP-I
28 treatment ($P>0.05$; Figure 6B), and 70% with CHX ($P>0.05$; Figure 6C). Viable
29 cell counts were reduced further by PVP-I (97%, $P<0.001$), whilst CHX was
30 less effective (22%, $P>0.05$).

Based the SEM images, it can be clearly shown that there is an increased cell number on the 3-D substrates, irrespective of treatment. The fibrous nature of the cellulose matrix creates a greater surface area. Interestingly, in the 3-D model *C. albicans* is observed mainly as yeast cells, which is reflected in the viable cell numbers reported above. However, on the 3-D substrate the dominant morphotype was suggestive of *P. aeruginosa*.

Statistical analysis reveals significant differences between treatments and biofilm substrates

Conventional culture and viability assays revealed significantly greater quantities of cells in the 3-D model of *P. aeruginosa* monoculture ($P < 0.001$ and $P < 0.0001$ respectively), as well as the triadic cultures (yeast CFU, $P < 0.0001$, bacteria CFU, $P < 0.01$, overall viability $P < 0.01$). However, there was some discrepancy between the two assays with regards to the *S. aureus* and *C. albicans* monocultures. The *S. aureus* monoculture was shown not to have significantly higher cells in the 3-D model by conventional culture ($P > 0.05$). Though, using the viability assay there were significantly ($P < 0.0001$), the reverse was true of *C. albicans* monocultures (culture, $P < 0.0001$, viability, $P > 0.05$). Molecular analysis also confirmed the number of viable cells within the 3-D cellulose triadic species model was significantly higher than within the 2-D model ($P < 0.001$). In the 3-D model, there was a significant decrease in the proportion of *S. aureus* in the biofilm, in both total and live composition ($P < 0.0001$), and also a decrease in the live composition of *C. albicans* ($P < 0.05$). SEM provided further evidence that irrespective of treatment and substrate, a significant level of biomass is retained, though notably more upon the cellulose 3-D matrix.

Further to this, there were also significant differences seen between the two models after treatment. Both conventional culture and viability assays revealed that when treated, CHX was less effective in the cellulose matrix model ($P < 0.05$), with the exception of *S. aureus* monoculture biofilms where culturable cells were in fact higher in the 2-D model ($P < 0.05$). PVP-I was

1 similarly effective in both models, with higher recalcitrance observed in the 3-D
2 model for *P. aeruginosa* ($P<0.05$) and the bacterial component of the triadic
3 biofilm ($P<0.01$). For both mono-species and triadic biofilms, treatments were
4 also shown to be less effective by live/dead qPCR on the 3-D model, with both
5 the number of total and live CFEs being significantly increased ($P<0.05$).
6 Proportional composition differences were seen after CHX treatment with a
7 significant decrease in both total and live *S. aureus* in the biofilm ($P<0.0001$).
8 This was also true of PVP-I treatment where all components of the triadic 3-D
9 cellulose matrix model differed in composition to that of the 2-D model
10 ($P<0.05$).

11 PCA was used to reduce the dimensionality of the viable cell data, and allowed
12 the data to be plotted along two principal components (Figure 7). Four distinct
13 clusters emerged; cluster 1 containing only untreated 2-D model; cluster 2 was
14 only PVP-I treated 2-D model; cluster 3 contained CHX treated 2-D model and
15 PVP-I treated 3-D model; cluster 4 containing untreated and CHX treated 3-D
16 model. These clusters were statistically distinct ($P<0.05$). Untreated samples
17 scored higher on PC1 (x axis), this is also true of CHX treated 3-D model,
18 which were indistinct from their untreated counterpart. Treated samples
19 generally scored lower on PC1, which is shown by the directionality arrows. 3-
20 D model biofilms generally scored higher on PC2 (y axis), with the exception of
21 CHX treated 2-D biofilms within cluster 1. Collectively, these data show that 2-
22 D models undergoing treatment can reveal clear effects from antimicrobial
23 challenge, whereas 3-D models are not subject to the same extent of dynamic
24 change.

25

1 Discussion

2 This study set out to test clinically relevant treatments on a newly developed *in*
3 *vitro* inter-kingdom triadic biofilm model that is more representative of the
4 physical environment and microbial composition of wounds infections. Based
5 on the methods employed, we report that our new developed wound model
6 supports significantly greater quantities of microorganisms, and that this
7 improved structure reduces the effectiveness of widely used topical
8 antimicrobial agents. Overall, irrespective of the model used, PVP-I treatment
9 was generally more effective than CHX in reducing bacterial, fungal and inter-
10 kingdom bioburden. This highlights the need to better understand the biofilm
11 environment, in particular the importance of mono-, multi-species, or indeed
12 inter-kingdom biofilms in these infections.

13 Models that recapitulate complex biofilm related diseases and test
14 antimicrobial agents are difficult. Moreover, the ways in which these models
15 are interrogated to generate meaningful data are often flawed. The use of
16 conventional plate counting is still wide spread despite the inherent bias
17 towards the outcome antimicrobial challenge. Innovative molecular based
18 methodologies that analyse viability tend to yield data that is accurate, both
19 qualitatively and quantitatively. Apparent “complete and efficient killing”
20 phenomenon demonstrated by conventional microbiological studies of wound
21 biofilms are not unusual (Hill, et al. 2010, Kart, et al. 2014), including on the
22 agents tested here on methicillin resistant *S. aureus*-*C. albicans* co-cultures
23 and *P. aeruginosa* only biofilms (Hoekstra, et al. 2016). However, molecular
24 viability analysis can often reveal a larger viable population of cells remaining
25 after treatment (Sherry, et al. 2016). This can be expected, given the nature of
26 the extracellular matrix combined with viable but non-culturable (VBNC), or
27 persister cells, which occur naturally within microbial communities.

28 The novel *in vitro* interkingdom biofilm model characterised herein consistently
29 showed higher cell counts and less effectiveness of the topical agents used
30 compared with biofilms on polystyrene substrates. This may be partially due to
31 the increased surface area within the cellulose matrix of the novel model. The
32 comparison against the standardised plastic substrate showed that although

1 they are extensively used for many applications (Capita et al. 2014, Kart, et al.
2 2014, Mottola et al. 2016, Naparstek et al. 2014, Santos et al. 2016), they are
3 not fully representative of the *in vivo* situation. It has been noted previously
4 that organisms grown with the support of hydrogel matrices are less
5 susceptible to antimicrobial treatments (Clutterbuck, et al. 2007, Percival, et al.
6 2007). Within 3-D structures such as these it has previously been noted that
7 varying metabolic states naturally exist, due to gradients of both oxygen and
8 nutrients (Rani et al. 2007). These gradients are thought to contribute to
9 tolerance of antimicrobials in biofilms, which could also contribute to the effects
10 seen here. This is indeed a limitation of widespread 2-D models. In our study,
11 this was especially evident with the CHX treatment; which although it
12 apparently effective in the 2-D model showed only a minimal effect on the 3-D
13 matrix probably mainly due to the high levels of *P. aeruginosa* within this model,
14 which has been found to be resistant to CHX at the wound wash concentration
15 (Salami et al. 2006). Interestingly, taking a PCA approach we showed that the
16 untreated and CHX treated cellulose models clustered together, indicating
17 there is little change in viable composition, which is reinforced by the other
18 results described herein. While the proportional make-up of the 2-D model was
19 roughly equally split between the three species, in the 3-D cellulose matrix
20 model *C. albicans* and *P. aeruginosa* dominated. *S. aureus* was present in the
21 cellulose matrix model at approximately $2 \times \log_{10}$ lower, which is also reflected
22 in SEM imaging. Conversely, *P. aeruginosa* can be observed covering the 3-D
23 mesh of the untreated cellulose matrix.

24 Innovative molecular based methodologies that analyse viability tend to yield
25 data that is accurate, both qualitatively and quantitatively. These have been
26 used to scrutinise and evaluate the impact of treatment of wound infections,
27 and are well described. Early wound model studies used qPCR to investigate
28 compositional changes within their chronic wound biofilm model (Dowd et al.
29 2009). PCR has previously been criticised for being too sensitive and
30 overestimating the population when compared to culture techniques, with this
31 being attributed to eDNA and the presence of dead cells (Castillo et al. 2006,
32 He and Jiang 2005). As table 2 illustrates, live/dead PCR is the most
33 expensive technique used in this work. Although qPCR approaches are more

expensive overall, these methods eliminate the subjectivity and non-specificity that are associated with conventional microbiology approaches. Moreover, detrimental interactions produced by *P. aeruginosa* phenazines have detrimental effects on hyphal growth and viability, effects difficult to decipher with conventional approaches (Hogan and Kolter 2002). With our approach, significant differences were demonstrated here in viability, however there was little difference seen between the biomass of untreated and treated biofilms (data not shown), which is consistent with other studies where CHX and PVP-I did not reduce biomass (Sherry et al. 2013, Tote et al. 2010).

No conclusive clinical studies exist which confirm the effectiveness of CHX in either diabetic foot ulcer or chronic wound infection. A study using a bioreactor to form an *in vitro* multi-species biofilm incorporating *Klebsiella pneumoniae*, *P. aeruginosa*, *S. aureus* and *Enterococcus faecalis* concluded that the effectiveness of CHX in controlling a pre-formed biofilm may be limited, especially on multi-species biofilms (Touzel et al. 2016).

Similarly, definitive clinical studies for PVP-I are lacking. A recent rat model study found that *P. aeruginosa* infected wounds irrigated with PVP-I had reduced bacterial counts both on the wound surface and within the tissue compared with irrigation with saline (Kanno et al. 2016). However, this model may be more relevant to skin preparation prior to surgery than to the management of chronic wounds. A Cochrane review of the use of antiseptics in pressure ulcers included PVP-I, but not CHX. The study concluded that the relative effects of systemic and topical antimicrobial treatments on pressure ulcers are not clear but the evidence was graded from moderate to low quality (Norman et al. 2015). More useful is the Cochrane review of antibiotics and antiseptics for venous leg ulcers, which concludes that while some evidence supports the use of cadexomer iodine more evidence is required before conclusions can be drawn about the effectiveness of PVP-I or CHX in healing venous leg ulceration (O'Meara et al. 2013).

Conclusions

This study highlights importance creating a polymicrobial *in vitro* biofilm reflective of the microflora of wounds, containing both fungal and bacterial components. Representative 3-D biofilm substrates showed an increased

1 resistance to antimicrobial wound washes compared to the 2-D plastic surfaces.
2 Indeed, PCA analysis was clearly able to discern how the models reacted to
3 different treatments. The necessity of using multiple viability techniques to
4 analyse different aspects of the biofilm is also recognised. Singular approaches
5 often only analyse one aspect of the biofilm, but by combining techniques
6 multiple outputs can be measured and analysed collectively. In practical terms,
7 this study shows that our ability to influence wound infections of a polymicrobial
8 and inter-kingdom nature are limited with simple treatments, particularly given
9 the resilient capacity of complex biofilms and their potential to remain and
10 seeding reservoirs. Further studies will be important in trying to maximise the
11 removal and decontamination of complex wound infections, potentially
12 reducing patient morbidity and mortality.

14 **Competing interests**

15 None of the authors have any competing interests.

17 **Acknowledgements**

18 We would like to thank Margaret Mullin (University of Glasgow) for her
19 assistance in scanning electron microscopy techniques, and Ian Davies (IPS
20 Converters) for supplying cellulose matrix used in the 3-D model.

References

- Alavi A, Sibbald RG, Mayer D, Goodman L, Botros M, Armstrong DG, Woo K, Boeni T, Ayello EA, Kirsner RS. 2014. Diabetic foot ulcers: part II. Management. *Journal of the American Academy of Dermatology*.70:21. e21-21. e24.
- Alvarez G, Gonzalez M, Isabal S, Blanc V, Leon R. 2013. Method to quantify live and dead cells in multi-species oral biofilm by real-time PCR with propidium monoazide. *AMB Express*.3:1.
- Appelgren P, Björnhagen V, Bragderyd K, Jonsson CE, Ransjö U. 2002. A prospective study of infections in burn patients. *Burns*.28:39-46.
- Atiyeh BS, Dibo SA, Hayek SN. 2009. Wound cleansing, topical antiseptics and wound healing. *International wound journal*.6:420-430.
- Capita R, Riesco-Peláez F, Alonso-Hernando A, Alonso-Calleja C. 2014. Exposure of *Escherichia coli* ATCC 12806 to sublethal concentrations of food-grade biocides influences its ability to form biofilm, resistance to antimicrobials, and ultrastructure. *Applied and environmental microbiology*.80:1268-1280.
- Castillo M, Martín-Orúe SM, Manzanilla EG, Badiola I, Martín M, Gasa J. 2006. Quantification of total bacteria, enterobacteria and lactobacilli populations in pig digesta by real-time PCR. *Veterinary microbiology*.114:165-170.
- Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. 2007. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. *Journal of clinical microbiology*.45:2819-2828.
- Clutterbuck AL, Cochrane CA, Dolman J, Percival SL. 2007. Evaluating antibiotics for use in medicine using a poloxamer biofilm model. *Annals of Clinical Microbiology and Antimicrobials*.6:1.
- Davies D. 2003. Understanding biofilm resistance to antibacterial agents. *Nature reviews Drug discovery*.2:114-122.
- Dowd S, Sun Y, Smith E, Kennedy J, Jones C, Wolcott R. 2009. Effects of biofilm treatments on the multi-species Lubbock chronic wound biofilm model. *Journal of wound care*.18.
- Dowd SE, Delton Hanson J, Rees E, Wolcott RD, Zischau AM, Sun Y, White J, Smith DM, Kennedy J, Jones CE. 2011. Survey of fungi and yeast in polymicrobial infections in chronic wounds. *J Wound Care*. Jan;20:40-47.
- Duthie E, Lorenz LL. 1952. Staphylococcal coagulase: mode of action and antigenicity. *Microbiology*.6:95-107.
- Erlandsen SL, Kristich CJ, Dunne GM, Wells CL. 2004. High-resolution visualization of the microbial glycocalyx with low-voltage scanning electron microscopy: dependence on cationic dyes. *The journal of histochemistry and*

1 cytochemistry : official journal of the Histochemistry Society. Nov;52:1427-1435.
2 Epub 2004/10/27.

3 Fazli M, Bjarnsholt T, Kirketerp-Møller K, Jørgensen B, Andersen AS, Krogfelt
4 KA, Givskov M, Tolker-Nielsen T. 2009. Nonrandom distribution of
5 *Pseudomonas aeruginosa* and *Staphylococcus aureus* in chronic wounds.
6 *Journal of clinical microbiology*.47:4084-4089.

7 Fonzi WA, Irwin MY. 1993. Isogenic strain construction and gene mapping in
8 *Candida albicans*. *Genetics*.134:717-728.

9 Grice EA, Segre JA. 2011. The skin microbiome. *Nature Reviews*
10 *Microbiology*.9:244-253.

11 Hammer O HD, Ryan PD. 2001. PAST: Paleontological statistics software
12 package for education and data analysis. *Journal*];

13 Harrison F, Roberts AE, Gabriliska R, Rumbaugh KP, Lee C, Diggle SP. 2015.
14 A 1,000-Year-Old Antimicrobial Remedy with Antistaphylococcal Activity.
15 *mBio*.6:e01129-01115.

16 Hartemann - Heurtier A, Robert J, Jacqueminet S, Ha Van G, Golmard J,
17 Jarlier V, Grimaldi A. 2004. Diabetic foot ulcer and multidrug - resistant
18 organisms: risk factors and impact. *Diabetic Medicine*.21:710-715.

19 He J-W, Jiang S. 2005. Quantification of enterococci and human adenoviruses
20 in environmental samples by real-time PCR. *Applied and Environmental*
21 *Microbiology*.71:2250-2255.

22 Hex N, Bartlett C, Wright D, Taylor M, Varley D. 2012. Estimating the current
23 and future costs of Type 1 and Type 2 diabetes in the UK, including direct
24 health costs and indirect societal and productivity costs. *Diabetic*
25 *Medicine*.29:855-862.

26 Hill KE, Malic S, McKee R, Rennison T, Harding KG, Williams DW, Thomas
27 DW. 2010. An in vitro model of chronic wound biofilms to test wound dressings
28 and assess antimicrobial susceptibilities. *Journal of Antimicrobial*
29 *Chemotherapy*.dkq105.

30 Hoekstra MJ, Westgate SJ, Mueller S. 2016. Povidone - iodine ointment
31 demonstrates in vitro efficacy against biofilm formation. *International wound*
32 *journal*.

33 Hogan DA, Kolter R. 2002. *Pseudomonas*-*Candida* interactions: an ecological
34 role for virulence factors. *Science*.296:2229-2232.

35 Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. 2010. Antibiotic resistance
36 of bacterial biofilms. *International journal of antimicrobial agents*.35:322-332.

- 1 James GA, Swogger E, Wolcott R, Secor P, Sestrich J, Costerton JW, Stewart
2 PS. 2008. Biofilms in chronic wounds. *Wound repair and regeneration*.16:37-
3 44.
- 4 Kanno E, Tanno H, Suzuki A, Kamimatsuno R, Tachi M. 2016.
5 Reconsideration of iodine in wound irrigation: the effects on *Pseudomonas*
6 *aeruginosa* biofilm formation. *Journal of Wound Care*.25:335-339.
- 7 Kart D, Tavernier S, Van Acker H, Nelis HJ, Coenye T. 2014. Activity of
8 disinfectants against multispecies biofilms formed by *Staphylococcus aureus*,
9 *Candida albicans* and *Pseudomonas aeruginosa*. *Biofouling*.30:377-383.
- 10 Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E, Winstanley C. 2012.
11 Use of artificial sputum medium to test antibiotic efficacy against *Pseudomonas*
12 *aeruginosa* in conditions more relevant to the cystic fibrosis lung. *Journal of*
13 *visualized experiments* : JoVE.e3857. Epub 2012/06/20.
- 14 MacDonald YG, Hait H, Lipsky B, Zasloff M, Holroyd K. 2002. Microbiological
15 profile of infected diabetic foot ulcers. *Diabetic Medicine*.19:1032-1034.
- 16 Miles A, Misra S, Irwin J. 1938. The estimation of the bactericidal power of the
17 blood. *Journal of Hygiene*.38:732-749.
- 18 Mottola C, Matias CS, Mendes JJ, Melo-Cristino J, Tavares L, Cavaco-Silva P,
19 Oliveira M. 2016. Susceptibility patterns of *Staphylococcus aureus* biofilms in
20 diabetic foot infections. *BMC microbiology*.16:119.
- 21 Naparstek L, Carmeli Y, Navon-Venezia S, Banin E. 2014. Biofilm formation
22 and susceptibility to gentamicin and colistin of extremely drug-resistant KPC-
23 producing *Klebsiella pneumoniae*. *Journal of Antimicrobial*
24 *Chemotherapy*.69:1027-1034.
- 25 Neut D, Tjeldens-Creusen EJ, Bulstra SK, van der Mei HC, Busscher HJ. 2011.
26 Biofilms in chronic diabetic foot ulcers-a study of 2 cases. *Acta*
27 *orthopaedica*.82:383-385.
- 28 Norman G, Dumville JC, Moore ZE, Tanner J, Christie J, Goto S. 2015.
29 Antibiotics and antiseptics for pressure ulcers. *The Cochrane Library*.
- 30 O'meara S, Cullum N, Majid M, Sheldon T. 2001. Systematic review of
31 antimicrobial agents used for chronic wounds. *British Journal of Surgery*.88:4-
32 21.
- 33 O'Meara S, Al-Kurdi D, Ologun Y, Ovington LG, Martyn-St James M,
34 Richardson R. 2013. Antibiotics and antiseptics for venous leg ulcers.
35 *Cochrane Database Syst Rev*.12.
- 36 Percival SL, Bowler PG, Dolman J. 2007. Antimicrobial activity of silver -
37 containing dressings on wound microorganisms using an in vitro biofilm model.
38 *International wound journal*.4:186-191.

1 Peters BM, Jabra-Rizk MA, Graeme A, Costerton JW, Shirtliff ME. 2012.
2 Polymicrobial interactions: impact on pathogenesis and human disease.
3 Clinical microbiology reviews.25:193-213.

4 Pozo J, Patel R. 2007. The challenge of treating biofilm - associated bacterial
5 infections. Clinical Pharmacology & Therapeutics.82:204-209.

6 Rahme LG, Stevens EJ, Wolfort SF, Shao J. 1995. Common virulence factors
7 for bacterial pathogenicity in plants and animals. Science.268:1899.

8 Ramage G, Rajendran R, Sherry L, Williams C. 2012a. Fungal biofilm
9 resistance. Int J Microbiol.2012:528521.

10 Ramage G, Zalewska A, Cameron DA, Sherry L, Murray C, Finnegan MB,
11 Loewy ZG, Jagger DC. 2012b. A comparative in vitro study of two denture
12 cleaning techniques as an effective strategy for inhibiting *Candida albicans*
13 biofilms on denture surfaces and reducing inflammation. Journal of
14 Prosthodontics.21:516-522.

15 Rani SA, Pitts B, Beyenal H, Veluchamy RA, Lewandowski Z, Davison WM,
16 Buckingham-Meyer K, Stewart PS. 2007. Spatial patterns of DNA replication,
17 protein synthesis, and oxygen concentration within bacterial biofilms reveal
18 diverse physiological states. Journal of bacteriology.189:4223-4233.

19 Salami AA, Imosemi IO, Owoeye OO, SALAMI A, IMOSEMI I, OWOEYE O.
20 2006. A comparison of the effect of chlorhexidine, tap water and normal saline
21 on healing wounds. Int J Morphol.24:673-676.

22 Sanchez MC, Marin MJ, Figuero E, Llama-Palacios A, Herrera D, Sanz M.
23 2013. Analysis of viable vs. dead *Aggregatibacter actinomycetemcomitans* and
24 *Porphyromonas gingivalis* using selective quantitative real-time PCR with
25 propidium monoazide. Journal of periodontal research. Apr;48:213-220. Epub
26 2012/09/11.

27 Sanchez MC, Marin MJ, Figuero E, Llama-Palacios A, Leon R, Blanc V,
28 Herrera D, Sanz M. 2014. Quantitative real-time PCR combined with propidium
29 monoazide for the selective quantification of viable periodontal pathogens in an
30 in vitro subgingival biofilm model. Journal of periodontal research. Feb;49:20-
31 28.

32 Santos R, Gomes D, Macedo H, Barros D, Tibério C, Veiga AS, Tavares L,
33 Castanho M, Oliveira M. 2016. Guar gum as a new antimicrobial peptide
34 delivery system against diabetic foot ulcers *Staphylococcus aureus* isolates.
35 Journal of Medical Microbiology.

36 Santucci S, Gobara S, Santos C, Fontana C, Levin A. 2003. Infections in a
37 burn intensive care unit: experience of seven years. Journal of Hospital
38 Infection.53:6-13.

1 Sherry L, Lappin G, O'Donnell L, Millhouse E, Millington OR, Bradshaw D, Axe
2 A, Williams C, Nile CJ, Ramage G. 2016. Viable compositional analysis of an
3 eleven species oral polymicrobial biofilm. *Frontiers in Microbiology*.7:912.

4 Sherry L, Millhouse E, Lappin DF, Murray C, Culshaw S, Nile CJ, Ramage G.
5 2013. Investigating the biological properties of carbohydrate derived fulvic acid
6 (CHD-FA) as a potential novel therapy for the management of oral biofilm
7 infections. *BMC Oral Health*.13:47.

8 Smith K, Collier A, Townsend EM, O'Donnell LE, Bal AM, Butcher J, Mackay
9 WG, Ramage G, Williams C. 2016. One step closer to understanding the role
10 of bacteria in diabetic foot ulcers: characterising the microbiome of ulcers.
11 *BMC microbiology*.16:1.

12 Snell JA, Loh N, Mahambrey T, Shokrollahi K. 2013. Clinical review: the critical
13 care management of the burn patient. *Crit Care*.17:241.

14 Strathmann M, Griebe T, Flemming H-C. 2000. Artificial biofilm model—a useful
15 tool for biofilm research. *Applied microbiology and biotechnology*.54:231-237.

16 Sun Y. 2010. Survey of fungi and yeast in polymicrobial infections in chronic
17 wounds. *J wound care*.20:40.

18 Tote K, Horemans T, Berghe DV, Maes L, Cos P. 2010. Inhibitory effect of
19 biocides on the viable masses and matrices of *Staphylococcus aureus* and
20 *Pseudomonas aeruginosa* biofilms. *Applied and environmental*
21 *microbiology*.76:3135-3142.

22 Touzel R, Sutton J, Wand M. 2016. Establishment of a multi-species biofilm
23 model to evaluate chlorhexidine efficacy. *Journal of Hospital Infection*.92:154-
24 160.

25 Weinstein RA, Mayhall CG. 2003. The epidemiology of burn wound infections:
26 then and now. *Clinical Infectious Diseases*.37:543-550.

27

Figure 1 – Antimicrobial wound washes exhibit cidal activity against polymicrobial 2-D biofilms. Bacterial and fungal biofilms were grown as mono (A) and triadic cultures (B) in a 2-D model, as previously described. Following development, biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. Monospecies (A) and triadic biofilms (B) were assessed by CFU. Viability was also assessed by the alamarBlue® viability assay (C). All testing was carried out in triplicate, on three separate occasions. Data represents mean \pm SD, statistical analysis compared untreated to treated biofilms (* p <0.05, ** p <0.01, *** p <0.001). #Indicates no cell growth.

Figure 2 – Molecular analysis demonstrates a significant microbial burden remains within 2-D biofilms following treatment. Bacterial and fungal monospecies biofilms were grown in a 2-D model, as previously described. Following development, biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. Live/Dead PCR was performed and colony-forming equivalents (CFE) were calculated from standard curves for *C. albicans* (A), *S. aureus* (B) and *P. aeruginosa* (C). Data represents mean \pm SD. * Represents statistical difference in total CFE values and # represents significant differences between live CFE values (* p <0.05, ** p <0.01, *** p <0.001). Data represents CFE values calculated from triplicates carried out on three separate occasions.

Figure 3 – Molecular analysis gives insight into cell death in triadic 2-D biofilms, while SEM reveals complex communities in the triadic model. Bacterial and fungal triadic biofilms were grown in a 2-D model, as previously described. Following development, biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. Live/Dead PCR was performed and colony-forming equivalents (CFE) were calculated from standard curves for untreated (A), PVP-I (B) and CHX (C). Data represents percentage composition calculated from CFE values from triplicates carried out on three separate occasions. SEM, shown in lower panels, was conducted as described in the methods. Note *P. aeruginosa* indicated by a solid white arrow, *S. aureus* by white arrow head, *C. albicans* by a black arrow. *C. albicans* is present in predominantly hyphae form; the bacteria can be seen attached to the hyphae. Bars represent 20 μ m on lower magnifications (\times 1000) and 2 μ m at higher magnification (inset, \times 6000).

Figure 4 – PVP-I shows superior killing activity over CHX on 3-D biofilms. Bacterial and fungal biofilms were grown as mono (A) and triadic cultures (B) in the 3-

D model, as previously described. Following development, biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. Monospecies (A) and triadic biofilms (B) were assessed by CFU. Viability was also assessed by the alamarBlue® viability assay (C). All testing was carried out in triplicate, on three separate occasions. Data represents mean \pm SD, statistical analysis compared untreated to treated biofilms (* p <0.05, ** p <0.01, *** p <0.001). #Indicates no cell growth.

Figure 5 - Molecular analysis demonstrates a significant microbial burden with limited activity of CHX on 3-D biofilms. Bacterial and fungal monospecies biofilms were grown in the 3-D model, as previously described. Following development, biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. Live/Dead PCR was performed and colony-forming equivalents (CFE) were calculated from standard curves for *C. albicans* (A), *S. aureus* (B) and *P. aeruginosa* (C). Data represents mean \pm SD. * Represents statistical difference in total CFE values and # represents significant differences between live CFE values (* p <0.05, ** p <0.01, *** p <0.001). Data represents CFE values calculated from triplicates carried out on three separate occasions.


Figure 6 – Molecular analysis show compositional changes after treatment, especially with PVP-I, and SEM confirms high levels of growth in the triadic 3-D model. Bacterial and fungal triadic biofilms were grown in the 3-D model, as previously described. Following development, biofilms were washed and treated with PVP-I (10%) or CHX (0.05%) for 24 h. Live/Dead PCR was performed and colony-forming equivalents (CFE) were calculated from standard curves for untreated (A), PVP-I (B) and CHX (C). Data represents percentage composition calculated from CFE values from triplicates carried out on three separate occasions. SEM, shown in lower panels, was conducted as described in the methods. Note *P. aeruginosa* indicated by a solid white arrow, *S. aureus* by white arrow head, *C. albicans* by a black arrow. In the 3-D model, *C. albicans* is seen as mostly yeast; here bacteria and yeast are seen in clusters upon the cellulose matrix. Bars represent 20 μ m on lower magnifications (\times 1000) and 2 μ m at higher magnification (inset, \times 6000).

Figure 7 – Principal Component Analysis shows little effect of CHX treatment on cellulose matrix biofilms, whilst treatment of the 2-D model caused a shift to new clusters. PCA reduces the dimensionality of the data to form clusters. The axes represent the two principal components of the data which showed the highest


1 variance. These cluster patterns showed treatment with CHX does not impact
2 cellulose matrix biofilms, and PVP-I caused a similar compositional change in the 3-D
3 model to that of CHX treatment in the 2-D model. • Untreated 2-D, + Untreated 3-D, ▫
4 PVP-I 2-D, ▫ PVP-I 3-D, × CHX 2-D, ○ CHX 3-D.




A






B



C











A



B



C

